Rethinking the Way we Fight Bacteria
New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D
R&D pharmaceutical companies are currently working on 34 antibacterial compounds (19 molecules and 15 vaccines), of which 8 are undergoing the final stages of demonstrating their efficacy, quality, and safety (phase 3 clinical trials).
This report produced by leading R&D based pharmaceutical companies highlights the scientific challenges associated with the development of new antibiotics and gives recommendations for new mechanisms to stimulate antibiotic R&D that are adapted to the unique dynamics of the market for antibiotics.
Source: International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Have Your Say
Rate this feature and give us your feedback in the comments section below
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.